BIORESTORATIVE THERAPIES INC (BRTX)

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity...

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — —...

Which stocks are moving before the opening bell on Tuesday?

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative...

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment...

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies,...

BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q4 2023

BRTX stock results show that BioRestorative Therapies beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage...

Friday 2/9 Insider Buying Report: BRTX, LCTX

BioRestorative stock tumbles on new warrants (NASDAQ:BRTX)

BioRestorative Therapies (BRTX) stock loses 54% as company announces agreements to exchange existing warrants for new ones at a reduced price. Read more here.

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (

BioRestorative stock climbs 8% amid data presentation for disc therapy (NASDAQ:BRTX)

BioRestorative Therapies (BRTX) stock climbed 8% after a presentation of Phase 2 data for its lumbar disc disease therapy BRTX-100 at a medical meeting. Read more here.

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference...

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

--Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem® program targeting obesity and metabolic disorders, including type...

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage...

BioRestorative Therapies' 10% shareholder Broadrick Dale increases holding (NASDAQ:BRTX)

BioRestorative Therapies (BRTX) disclosed in an SEC filing on Monday that its 10% shareholder Broadrick Dale acquired an aggregate of 20,000 company shares on Sept 14 - Sept 15 for...

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

--BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to Supply Biologics for Cosmetic Applications in Strategic Agreement ...